Navigation Links
YM BIOSCIENCES ANNOUNCES OFFER FOR CYTOPIA LTD., AN AUSTRALIAN CANCER-FOCUSED DEVELOPMENT COMPANY
Date:10/5/2009

MISSISSAUGA, ON, Oct. 5 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex:YMI, TSX:YM, AIM:YMBA), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, today announced it has proposed to merge Cytopia Ltd., a clinical-stage, Melbourne-based drug development company, into YM. Cytopia's lead products are CYT997, a novel vascular disrupting agent (VDA) currently in Phase II trials, and CYT387, a novel, orally-active JAK2 inhibitor that recently received clearance from the FDA to commence a Phase I trial in myeloproliferative disorders.

"After assessing numerous global in-licensing opportunities, we determined that Cytopia's products were an ideal complement to our current portfolio," said David Allan, Chairman and CEO of YM BioSciences. "While the continued development of our lead product nimotuzumab remains our highest priority, we believe the timing is appropriate to expand our pipeline, consistent with our business model, leveraging our existing resources and expertise to select from the opportunities offered to us in order to continue to enhance the value of YM."

Cytopia's lead product, CYT997, has demonstrated potent disruption of existing tumor vasculature and therefore has the potential to synergize with existing marketed anti-angiogenesis agents, such as Avastin(R), which only target novel blood vessel formation. CYT997's availability in both oral and intravenous formulations differentiates it from most other VDAs, including those more advanced in clinical development, which are typically available in intravenous form only. Phase I trial results from the intravenous formulation of CYT997 were presented at ASCO in 2008 and results from the Phase I oral study were presented at ASCO 2009 demonstrating that both formulations were well-tolerated and showed preliminary signs of efficacy as determined by measures of tumor v
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... (PRWEB) May 17, 2013 •    First of ... Certified for sustainability ,     New facility will help ... , Syngenta unveiled its new crop ... the company’s RTP Innovation Center. The first of its ... to simulate any agricultural climate and precisely measure plant ...
(Date:5/17/2013)... 17, 2013  Cellular Biomedicine Group (OTCQB: CBMG) ... of the total projected enrollment required for its ... preliminary efficacy of the medical technology haMPC (Human ... (KOA). To date the trial has had no ... Phase I open label clinical research trial for ...
(Date:5/17/2013)... Calif. , May 17, 2013 /PRNewswire-iReach/ -- ... has been reached with Switzerland ... of anti-infective human monoclonal antibody (mAb) products, and ... human mAb products for treatment of infections by ... Staphylococcus aureus , Pseudomonas aeruginosa , ...
(Date:5/17/2013)... Men’s skin is biologically different than women’s skin,( says skin ... known to react more aggressively when hormones change, and acne ... other acne causing factors like P.acnes bacteria and excess dirt ... unsightly acne scars. Adult acne treatment, Probiotic Action shares new ... to reduce and prevent acne scarring. , In order to ...
Breaking Biology Technology:Syngenta Opens Unique $72 Million Advanced Crop Lab 2Syngenta Opens Unique $72 Million Advanced Crop Lab 3Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 3Adult Acne Treatment, Probiotic Action Shares New Insight on Why Men’s Skin Scars from Acne and How to Prevent It 2
... Prostate, Lung and Brain Tumor ... Treatment, ... global leader in the field of radiosurgery,today announced key clinical presentation highlights ... in,Scottsdale, Ariz., At this year,s CyberKnife Users, meeting eight presentations reported,on ...
... Feb. 12 AdvanDx announced it has named,Else ... Dako A/S, as Vice,President of Sales and Marketing. ... AdvanDx,s fast, accurate and easy-to-use in vitro,molecular diagnostic ... infectious pathogens. Ms. Trautner previously managed an,organization of ...
... SAN FRANCISCO, Calif., Feb. 12 Rigel,Pharmaceuticals, Inc. (Nasdaq: ... quarter and year ended December 31, 2007., For ... loss of $19.0,million, or $0.61 per share, compared to ... in the fourth quarter of 2006. Weighted average shares,outstanding ...
Cached Biology Technology:CyberKnife Users' Meeting Highlights Major Clinical Data Milestones and Emerging Trends 2CyberKnife Users' Meeting Highlights Major Clinical Data Milestones and Emerging Trends 3CyberKnife Users' Meeting Highlights Major Clinical Data Milestones and Emerging Trends 4Molecular Diagnostics Leader AdvanDx Taps Former Dako Executive Vice President to Lead Global Sales and Marketing Expansion 2Rigel Announces Fourth Quarter and Year End 2007 Financial Results 2Rigel Announces Fourth Quarter and Year End 2007 Financial Results 3Rigel Announces Fourth Quarter and Year End 2007 Financial Results 4
(Date:5/17/2013)... LEMONT, Ill. An international team ... internal structure and cell movement inside a living frog ... showcases a new method to advance biological research and ... at Northwestern University and the Karlsruher Institut fr Technologie ... at the U.S. Department of Energy,s Argonne National Laboratory, ...
(Date:5/16/2013)... a fast food restaurant had a higher body mass ... fast food, according to researchers at The University of ... particularly strong among those with a lower income. ... American Journal of Public Health indicates higher BMI ... and among lower-income African-Americans, the density, or number, of ...
(Date:5/16/2013)... The endothelium, the cellular layer lining the body,s ... few hundred nanometers in thickness, this super-tenuous structure ... tissue compression to create a unique and highly ... partition tissues from the body,s circulatory system. , ... barrier must be physically breached to enable ...
Breaking Biology News(10 mins):New X-ray method shows how frog embryos could help thwart disease 2Body mass index of low income African-Americans linked to proximity of fast food restaurants 2Body mass index of low income African-Americans linked to proximity of fast food restaurants 3Endothelium, heal thyself 2Endothelium, heal thyself 3Endothelium, heal thyself 4
... at Penn State have shed light on some of the processes ... proteins are produced at the correct time, place, and amount in ... evolution of the DNA regions that regulate genes. The team ... are thought to turn on genes that play an important role ...
... Sandcastle worms live in intertidal surf, building sturdy tube-shaped ... natural glue. University of Utah bioengineers have made a synthetic ... used within several years to repair shattered bones in knees, ... of the small pieces together," says Russell Stewart, associate professor ...
... online information system created by D. Ross Robertson, ... and Coeus Knowledge Systems makes it possible for ... managers to identify and generate publishable maps for ... of the Tropical Eastern Pacific Online Information System ...
Cached Biology News:Scientists shed light on evolution of gene regulation 2Scientists shed light on evolution of gene regulation 3Superglue from the sea 2Superglue from the sea 3Superglue from the sea 4Superglue from the sea 5Smithsonian puts tropical Eastern-Pacific shore fishes online 2Smithsonian puts tropical Eastern-Pacific shore fishes online 3
... to Ki67 - Proliferation Marker, prediluted ... related nuclear protein, expressed by proliferating cells ... cycle (G1, S, G2 and M phase). ... Ki67 antibodies are useful in establishing the ...
UBC13 Antibody...
Request Info...
HLA II DG+DR+DP Monoclonal Antibody, Purified, Unconjugated, Clone: IQU9 This antibody is specific for the monomorphic determinant of the HLA Class II beta chains of the human MHC (28 kDa)....
Biology Products: